Navigation Links
Head and Neck Cancer Vaccine Targets Proteins to Create Immune Response

Researchers have developed a vaccine strategy for head and neck cancer that targets multiple peptides (parts of proteins) to activate the immune system// to attack tumors.

The researchers created the vaccine to target a tumor suppressor gene called p53, which is mutated in most cancers and associated with poor clinical outcomes. Previous research has determined that mutated p53 also expresses unaltered, or "wild-type," p53 peptides in tumors. When presented on dendritic cells, these wild-type p53 peptides may induce an immune response to strengthen the body's natural defenses against cancer and decrease the chance of cancer recurrence and the formation of secondary tumors.

"The key to our strategy is to select those p53 peptides that can best activate the immune system and induce it to produce immune cells able to recognize and eliminate the tumor," said Theresa Whiteside, Ph.D., who in collaboration with Albert DeLeo, Ph.D., directed the study. Both investigators are professors of pathology and immunology at the University of Pittsburgh School of Medicine. "Through animal models and human cells in culture, we have found that this strategy is very effective at stimulating T cells into action," said Dr. Whiteside, who also directs UPCI's Immunologic Monitoring and Cellular Products Laboratory. According to Dr. DeLeo, the vaccine based on these findings also could be relevant to other types of cancer given that the loss of p53 function is a common feature across many cancers.

The vaccine is based on three peptides derived from p53 that target killer T cells and helper T cells. Although killer T cells directly destroy tumor cells, they are assisted by helper T cells that secrete small proteins called cytokines to regulate or "help" the immune response.

Given that the proof of principle for the vaccine has been determined, a phase I clinical trial of the vaccine has begun at the University of Pittsburgh Cancer Institut e to assess its safety in head and neck cancer patients.

Head and neck cancer accounts for about 5 percent of all newly diagnosed cancers in the United States. More than two-thirds of head and neck cancer patients have a locally advanced stage when diagnosed and have a poor five-year survival rate even after treatment.

Source-Eurekalert
'"/>




Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Consensus on "Combination Therapy" for Breast Cancer
6. Cancers of Colon & Rectum linked to Cigarette Smoking
7. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
8. The Cancer Rumour mill working over time
9. Cancer drugs in development nearly doubled since 1995
10. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
11. Cancer patients turning to Internet for information
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/25/2017)... (PRWEB) , ... July 25, 2017 , ... ... Health, as medical director. Dr. Negrette has more than a decade of experience ... has worked closely with individuals fighting addictions, eating disorders, psychotic and manic conditions, ...
(Date:7/24/2017)... ... July 24, 2017 , ... Engineers at the University ... it produces the same kind of electrical energy that the body uses. , ... moving electrons. This flow of electrons out of the battery is generated by moving ...
(Date:7/24/2017)... ... 24, 2017 , ... Cosmetic Town, an online plastic surgery information community, announces ... on a daily basis. , The new video series will feature board-certified doctors ... their practices. , When asked about the new video series, the senior editor ...
(Date:7/24/2017)... IQUITOS, Peru (PRWEB) , ... July 24, 2017 ... ... plans for $1,000 total in scholarship awards to be awarded annually to and ... who demonstrate an interest in bringing awareness to Amazonian plant medicine. To apply ...
(Date:7/24/2017)... ... July 24, 2017 , ... The Topricin Companies, formerly ... for Topricin’s revolutionary, natural, after-burn skin care product, Topricin After Burn Cream. ... long term skin conditions, including cancer. In the short term, overexposure to ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... 2017 It should come as no surprise to ... in the midst of a crippling opioid epidemic. According to ... number of overdose deaths from opiate-based medications has quadrupled, Says, ... million dead from 2001 to 2015". During this time, the ... similarly quadrupled, drawing a compelling link between prescription and eventual ...
(Date:7/12/2017)... CarpalAID is a revolutionary new product that relieves painful ... Carpal tunnel syndrome affects more than 8 million people a year. ... men. The common methods of treating CTS are painful surgery, the ... or gloves. ... CarpalAID is a clear patch worn on the palm of ...
(Date:7/11/2017)... Md. , July 11, 2017  The global ... estimated revenues of approximately $394.1 million in 2016.  Although ... trend of solid growth, in particular as a result ... clinical practice, and the recent introduction of a significant ... need for less-invasive testing of tumor biomarkers to guide ...
Breaking Medicine Technology: